Cencora (COR) Q4 FY2026 revenue $88.4 billion vs $88.9 billion est.; adj. EPS $4.66 vs $4.63 est.
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Cencora reported fiscal fourth-quarter revenue of $88.4 billion, up 5.5% year over year but just below the $88.9 billion analyst estimate, while adjusted diluted EPS of $4.66 beat the $4.63 consensus and rose 21.4%. Full-year revenue reached $337.4 billion, up 5.0%, with adjusted EPS of $17.97, and GAAP diluted EPS swung to $2.71 from a prior-year loss of $1.75. The drug distributor guided fiscal 2027 adjusted EPS to $19.40–$19.75, implying 8–10% growth, and raised its quarterly dividend by 10%. CEO Robert P. Mauch credited the OneOncology acquisition with expanding the company's MSO platform and said a new operating model uniting its specialty businesses will sharpen execution. Cencora also introduced new reportable segments with long-term growth targets, making segment-level disclosure and the fiscal 2027 guidance trajectory the items to watch.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.
Named in this story
Cencora (COR), Robert P. Mauch, OneOncology
A linked name opens that asset's sentiment page.